Results 151 to 160 of about 254,342 (304)

Fabrication, Properties, and Applications of Scaffolds for Bone Tissue Regeneration

Advanced Materials Technologies, EarlyView.
This review explores cutting‐edge biomaterials and fabrication techniques for scaffolds in bone tissue regeneration. It conducts a critical comparison of various strategies, meticulously analyzes the key contradictions in the field, and outlines an integrated development path spanning from biomaterial selection to clinical application, while ...
Shangsi Chen, Min Wang
wiley   +1 more source

Lattice Structures for Bone Replacement: The Intersection of Bone Biomechanics, Lattice Design, and Additive Manufacturing

Advanced Materials Technologies, EarlyView.
This review outlines how understanding bone's biology, hierarchical architecture, and mechanical anisotropy informs the design of lattice structures that replicate bone morphology and mechanical behavior. Additive manufacturing enables the fabrication of orthopedic implants that incorporate such structures using a range of engineering materials ...
Stylianos Kechagias, Maxwell J. Munford, Frederik C.H. Masure, Richard J. van Arkel, Reece N Oosterbeek   +4 more
wiley   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Corrigendum to "Hypersensitivity reactions to iodinated radiocontrast media: Cluster analysis reveals distinct clinical phenotypes" [World Allergy Organ J 15(9) (2022 Aug 27) 100680]. [PDF]

World Allergy Organ J
Srisuwatchari W, Vo T, Gauthier A, Molinari N, Schrijvers R, Demoly P, Chiriac AM.   +6 more
europepmc   +1 more source

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

Advanced Science, EarlyView.
Itch‐induced tick removal (IITR): An acquired neuroimmune mechanism, itch‐induced tick removal, develops after repeated tick exposure, mobilizing T cells and macrophages at the tick bite site to trigger a rapid scratching response that facilitates timely tick removal within a critical window that preces the transmission of many tick‐borne pathogens ...
Johannes S. P. Doehl, Tiago D. Serafim, Serena Doh, Charles S. Grugan, Eva Iniguez, Luana Rogerio, Ronja Frigard, Ranadhir Dey, Pedro Cecilio, Xinglong Gu, Pang‐Yen Tseng, Aline da Silva Moreira, Mahnaz Minai, James Oristian, Hans Ackerman, Steven Brooks, Caroline Percopo, Siu‐Ping Ng, Derron A. Alves, Lucas Tirloni, Jennifer M. Anderson, Adriana Marques, Fabiano Oliveira, Shaden Kamhawi, Daniel E. Sonenshine, José M. C. Ribeiro, Mark Hoon, Jesus G. Valenzuela   +27 more
wiley   +1 more source

Language barriers in pediatric food allergy care: A single-center study on healthcare disparities. [PDF]

PLoS One
Wong KH, Pandya N, McCollum S, Shabanova V, Soffer GK.   +4 more
europepmc   +1 more source

Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery

Advanced Science, EarlyView.
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu   +6 more
wiley   +1 more source

Corrigendum to "Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign" [World Allergy Organ J 18(8) (2025 Jul 28) 101095. doi: 10.1016/j.waojou.2025.101095]. [PDF]

World Allergy Organ J
Nicola S, Badiu I, Rashidy N, Saracco E, Montabone E, Sardo LL, Boem M, Marmora V, Corradi F, Ricotti A, Borrelli R, Rolla G, Negrini S, Brussino L.   +13 more
europepmc   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Evaluation of pediatric patients with drug allergy confirmed by in vivo diagnostic tests. [PDF]

Pediatr Allergy Immunol
İpek Demir K, Yılmaz D, Güvenir FA, Giniş T, İslamoğlu C, Şengül Emeksiz Z, Karaatmaca B, Toyran M, Civelek E, Misirlioğlu ED.   +9 more
europepmc   +1 more source